RESUMEN
Epidemic diseases have caused huge harm to the society. Traditional Chinese medicine(TCM) has made great contributions to the prevention and treatment of them. It is of great reference value for fighting diseases and developing drugs to explore the medication law and mechanism of TCM under TCM theory. In this study, the relationship between the TCM theory of cold pestilence and modern epidemic diseases was investigated. Particularly, the the relationship of coronavirus disease 2019(COVID-19), severe acute respiratory syndrome(SARS), and influenza A(H1 N1) with the cold pestilence was identified and analyzed. The roles of TCM theory of cold pestilence in preventing and treating modern epidemic diseases were discussed. Then, through data mining and textual research, prescriptions for the treatment of cold pestilence were collected from major databases and relevant ancient books, and their medication laws were examined through analysis of high-frequency medicinals and medicinal pairs, association rules analysis, and cluster analysis. For example, the prescriptions with high confidence levels were identified: "Glycyrrhizae Radix et Rhizoma-Bupleuri Radix-Paeoniae Radix Alba" "Glycyrrhizae Radix et Rhizoma-Pinelliae Rhizoma-Bupleuri Radix", and TCM treatment methods with them were analyzed by clustering analysis to yield the medicinal combinations: "Zingiberis Rhizoma-Aconiti Lateralis Radix Praeparata-Ginseng Radix et Rhizoma" "Poria-Atractylodis Macrocephalae Rhizoma" "Cinnamomi Ramulus-Asari Radix et Rhizoma" "Citri Reticulatae Pericarpium-Perillae Folium" "Pinelliae Rhizoma-Magnoliae Officinalis Cortex-Atractylodis Rhizoma" "Paeoniae Radix Alba-Angelicae Sinensis Radix-Glycyrrhizae Radix et Rhizoma-Bupleuri Radix-Scutellariae Radix-Rhizoma Zingiberis Recens" "Ephedrae Herba-Armeniacae Semen Amarum-Gypsum Fibrosum" "Chuanxiong Rhizoma-Notopterygii Rhizoma et Radix-Angelicae Dahuricae Radix-Platycodonis Radix-Saposhnikoviae Radix". Then, according to the medication law for cold pestilence, the antiviral active components of medium-frequency and high-frequency medicinals were retrieved. It was found that these components exerted the antiviral effect by inhibiting virus replication, regulating virus proteins and antiviral signals, and suppressing protease activity. Based on network pharmacology, the mechanisms of the medicinals against severe acute respiratory syndrome coronavirus(SARS-CoV), 2019 novel coronavirus(2019-nCoV), and H1 N1 virus were explored. It was determined that the key targets were tumor necrosis factor(TNF), endothelial growth factor A(VEGFA), serum creatinine(SRC), epidermal growth factor receptor(EGFR), matrix metalloproteinase 9(MMP9), mitogen-activated protein kinase 14(MAPK14), and prostaglandin-endoperoxide synthase 2(PTGS2), which were involved the mitogen-activated protein kinase(MAPK) pathway, advanced glycation end-products(AGE)-receptor for AGE(RAGE) pathway, COVID-19 pathway, and mTOR pathway. This paper elucidated the medication law and mechanism of TCM for the prevention and treatment of epidemic diseases under the guidance of TCM theory of cold pestilence, in order to build a bridge between the theory and modern epidemic diseases and provide reference TCM methods for the prevention and treatment of modern epidemic diseases and ideas for the application of data mining to TCM treatment of modern diseases.
Asunto(s)
Aconitum , Control de Enfermedades Transmisibles , Enfermedades Transmisibles , Medicamentos Herbarios Chinos , Epidemias , Medicina Tradicional China , Pinellia , Antivirales , COVID-19/epidemiología , Sulfato de Calcio , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/virología , Creatinina , Ciclooxigenasa 2 , Medicamentos Herbarios Chinos/uso terapéutico , Factores de Crecimiento Endotelial , Epidemias/prevención & control , Receptores ErbB , Humanos , Metaloproteinasa 9 de la Matriz , Proteína Quinasa 14 Activada por Mitógenos , SARS-CoV-2 , Serina-Treonina Quinasas TOR , Factores de Necrosis Tumoral , Tratamiento Farmacológico de COVID-19RESUMEN
Infectious diseases and infections remain a leading cause of death in low-income countries and a major risk to vulnerable groups, such as infants and the elderly. The immune system plays a crucial role in the susceptibility, persistence, and clearance of these infections. With 70-80% of immune cells being present in the gut, there is an intricate interplay between the intestinal microbiota, the intestinal epithelial layer, and the local mucosal immune system. In addition to the local mucosal immune responses in the gut, it is increasingly recognized that the gut microbiome also affects systemic immunity. Clinicians are more and more using the increased knowledge about these complex interactions between the immune system, the gut microbiome, and human pathogens. The now well-recognized impact of nutrition on the composition of the gut microbiota and the immune system elucidates the role nutrition can play in improving health. This review describes the mechanisms involved in maintaining the intricate balance between the microbiota, gut health, the local immune response, and systemic immunity, linking this to infectious diseases throughout life, and highlights the impact of nutrition in infectious disease prevention and treatment.
Asunto(s)
Enfermedades Transmisibles/inmunología , Enfermedades Transmisibles/microbiología , Microbioma Gastrointestinal/fisiología , Sistema Inmunológico/microbiología , Fenómenos Fisiológicos de la Nutrición/inmunología , Anciano , Femenino , Humanos , Inmunidad Mucosa , Lactante , Mucosa Intestinal/inmunología , Mucosa Intestinal/microbiología , MasculinoRESUMEN
The emergence of antimicrobial resistance (AMR) has urged researchers to explore therapeutic alternatives, one of which includes the use of natural plant products such as essential oils (EO). In fact, EO obtained from clove, oregano, thymus, cinnamon bark, rosemary, eucalyptus, and lavender have been shown to present significant inhibitory effects on bacteria, fungi, and viruses; many studies have been done to measure EO efficacy against microorganisms. The strategy of combinatory effects via conventional and non-conventional methods revealed that the combined effects of EO-EO or EO-antibiotic exhibit enhanced efficacy. This paper aims to review the antimicrobial effects of EO, modes of EO action (membrane disruption, efflux inhibition, increase membrane permeability, and decrease in intracellular ATP), and their compounds' potential as effective agents against bacteria, fungi, and viruses. It is hoped that the integration of EO applications in this work can be used to consider EO for future clinical applications.
Asunto(s)
Antibacterianos/uso terapéutico , Enfermedades Transmisibles/tratamiento farmacológico , Aceites Volátiles/uso terapéutico , Plantas/química , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Enfermedades Transmisibles/microbiología , Sinergismo Farmacológico , Hongos/efectos de los fármacos , Humanos , Aceites Volátiles/farmacología , Aceites de Plantas/farmacología , Aceites de Plantas/uso terapéutico , Virus/efectos de los fármacosRESUMEN
Despite being nearly 10 months into the COVID-19 (coronavirus disease 2019) pandemic, the definitive animal host for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the causal agent of COVID-19, remains unknown. Unfortunately, similar problems exist for other betacoronaviruses, and no vouchered specimens exist to corroborate host species identification for most of these pathogens. This most basic information is critical to the full understanding and mitigation of emerging zoonotic diseases. To overcome this hurdle, we recommend that host-pathogen researchers adopt vouchering practices and collaborate with natural history collections to permanently archive microbiological samples and host specimens. Vouchered specimens and associated samples provide both repeatability and extension to host-pathogen studies, and using them mobilizes a large workforce (i.e., biodiversity scientists) to assist in pandemic preparedness. We review several well-known examples that successfully integrate host-pathogen research with natural history collections (e.g., yellow fever, hantaviruses, helminths). However, vouchering remains an underutilized practice in such studies. Using an online survey, we assessed vouchering practices used by microbiologists (e.g., bacteriologists, parasitologists, virologists) in host-pathogen research. A much greater number of respondents permanently archive microbiological samples than archive host specimens, and less than half of respondents voucher host specimens from which microbiological samples were lethally collected. To foster collaborations between microbiologists and natural history collections, we provide recommendations for integrating vouchering techniques and archiving of microbiological samples into host-pathogen studies. This integrative approach exemplifies the premise underlying One Health initiatives, providing critical infrastructure for addressing related issues ranging from public health to global climate change and the biodiversity crisis.
Asunto(s)
Investigación Biomédica/normas , Enfermedades Transmisibles/patología , Historia Natural/normas , Zoonosis/patología , Animales , Biodiversidad , Investigación Biomédica/tendencias , COVID-19/patología , COVID-19/virología , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/parasitología , Enfermedades Transmisibles/virología , Interacciones Huésped-Patógeno , Humanos , Museos/normas , SARS-CoV-2/clasificación , SARS-CoV-2/fisiología , Manejo de Especímenes , Zoonosis/microbiología , Zoonosis/parasitología , Zoonosis/virologíaRESUMEN
Introduction. Signal transducer and activator of transcription 3 (STAT3) deficiency is a rare primary immunodeficiency associated with increased susceptibility to bacterial and fungal infections, notably pulmonary aspergillosis.Aim. We describe the emergence of azole-resistant Aspergillus fumigatus infections in STAT3-deficient patients.Methodology. During a retrospective study of 13 pulmonary aspergillosis cases in STAT3-deficient patients conducted in France, we identified patients infected with azole-resistant A. fumigatus isolates.Results. Two out of the 13 STAT3-deficient patients with aspergillosis had azole-resistant A. fumigatus infection, indicating an unexpectedly high prevalence of resistance. The first patient with STAT3 deficiency presented several flares of allergic bronchopulmonary aspergillosis-like episodes. He was chronically infected with two azole-resistant A. fumigatus isolates (TR34/L98). Despite prolonged antifungal treatment, including caspofungin and amphotericin B, the patient was not able to clear the azole-resistant A. fumigatus. The second patient had chronic cavitary pulmonary aspergillosis (CCPA). The A. fumigatus isolate was initially azole susceptible but harboured three F46Y, M172V and E427K point mutations. Despite prolonged antifungal therapies, lesions worsened and the isolate became resistant to all azoles. Surgery and caspofungin treatments were then required to cure CCPA. Resistance was probably acquired from the environment (TR34/L98) in the first case whereas resistance developed under antifungal treatments in the second case. These infections required long-term antifungal treatments and surgery.Conclusions. The emergence of azole-resistant A. fumigatus infections in STAT3-deficiency dramatically impacts both curative and prophylactic antifungal strategies. Physicians following patients with primary immune-deficiencies should be aware of this emerging problem as it complicates management of the patient.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Azoles/uso terapéutico , Farmacorresistencia Fúngica/efectos de los fármacos , Aspergilosis Pulmonar/tratamiento farmacológico , Aspergilosis Pulmonar/genética , Factor de Transcripción STAT3/deficiencia , Adulto , Anfotericina B/uso terapéutico , Caspofungina/uso terapéutico , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/genética , Enfermedades Transmisibles/microbiología , Farmacorresistencia Fúngica/genética , Francia , Proteínas Fúngicas/genética , Genotipo , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos , Adulto JovenRESUMEN
INTRODUCTION: Companion diagnostics (CDx) are important in oncology therapeutic decision-making, but specific regulatory-approved CDx for infectious disease treatment are officially lacking. While not approved as CDx, several ID diagnostics are used as CDx. The diagnostics community, manufacturers, and regulatory agencies have made major efforts to ensure that diagnostics for new antimicrobials are available at or near release of new agents. AREAS COVERED: This review highlights the status of Complementary and companion diagnostic (c/CDx) in the infectious disease literature, with a focus on genotypic antimicrobial resistance testing against pathogens as a class of diagnostic tests. EXPERT OPINION: CRISPR, sepsis markers, and narrow spectrum antimicrobials, in addition to current and emerging technologies, present opportunities for infectious disease c/CDx. Challenges include slow guideline revision, high costs for regulatory approval, lengthy buy in by agencies, discordant pharmaceutical/diagnostic partnerships, and higher treatment costs. The number of patients and available medications used to treat different infectious diseases is well suited to support competing diagnostic tests. However, newer approaches to treatment (for example, narrow spectrum antibiotics), may be well suited for a small number of patients, i.e. a niche market in support of a CDx. The current emphasis is rapid and point-of-care (POC) diagnostic platforms as well as changes in treatment.
Asunto(s)
Antiinfecciosos/uso terapéutico , Enfermedades Transmisibles/tratamiento farmacológico , Farmacorresistencia Microbiana/genética , Pruebas de Sensibilidad Microbiana , Técnicas de Diagnóstico Molecular , Pruebas en el Punto de Atención , Medicina de Precisión/métodos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antiinfecciosos/farmacología , Antivirales/farmacología , Antivirales/uso terapéutico , Sistemas CRISPR-Cas , Enfermedades Transmisibles/diagnóstico , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/virología , Aprobación de Recursos , Aprobación de Drogas , Desarrollo de Medicamentos , Técnicas de Genotipaje , Humanos , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid receptors being part of the endocannabinoid system present in animals. Over the years a growing body of scientific evidence has been gathered, suggesting that these compounds have therapeutic potential. In this article, we review the classification of cannabinoids, the molecular mechanisms of their interaction with animal cells as well as their potential application in the treatment of human diseases. Specifically, we focus on the research concerning the anticancer potential of cannabinoids in preclinical studies, their possible use in cancer treatment and palliative medicine, as well as their influence on the immune system. We also discuss their potential as therapeutic agents in infectious, autoimmune, and gastrointestinal inflammatory diseases. We postulate that the currently ongoing and future clinical trials should be accompanied by research focused on the cellular and molecular response to cannabinoids and Cannabis extracts, which will ultimately allow us to fully understand the mechanism, potency, and safety profile of cannabinoids as single agents and as complementary drugs.
Asunto(s)
Cannabinoides/farmacología , Cannabinoides/uso terapéutico , Animales , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Apoptosis/efectos de los fármacos , Cannabinoides/química , Cannabis/química , Técnicas de Química Sintética , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/virología , Humanos , Sistema Inmunológico/efectos de los fármacos , Sistema Inmunológico/inmunología , Sistema Inmunológico/metabolismo , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Receptores de Cannabinoides/metabolismoRESUMEN
Antimicrobial resistance is one of the major public health threats of the 21st century. There is a pressing need to adopt more efficient treatment strategies in order to prevent the emergence and spread of resistant strains. The common approach is to treat patients with high drug doses, both to clear the infection quickly and to reduce the risk of de novo resistance. Recently, several studies have argued that, at least in some cases, low-dose treatments could be more suitable to reduce the within-host emergence of antimicrobial resistance. However, the choice of a drug dose may have consequences at the population level, which has received little attention so far. Here, we study the influence of the drug dose on resistance and disease management at the host and population levels. We develop a nested two-strain model and unravel trade-offs in treatment benefits between an individual and the community. We use several measures to evaluate the benefits of any dose choice. Two measures focus on the emergence of resistance, at the host level and at the population level. The other two focus on the overall treatment success: the outbreak probability and the disease burden. We find that different measures can suggest different dosing strategies. In particular, we identify situations where low doses minimize the risk of emergence of resistance at the individual level, while high or intermediate doses prove most beneficial to improve the treatment efficiency or even to reduce the risk of resistance in the population.
Asunto(s)
Enfermedades Transmisibles/tratamiento farmacológico , Antiinfecciosos/administración & dosificación , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/transmisión , Biología Computacional , Simulación por Computador , Brotes de Enfermedades/estadística & datos numéricos , Relación Dosis-Respuesta a Droga , Farmacorresistencia Microbiana/genética , Epidemias/estadística & datos numéricos , Objetivos , Interacciones Microbiota-Huesped , Humanos , Modelos Biológicos , Mutación , Medicina de Precisión , Probabilidad , Análisis de Sistemas , Resultado del TratamientoRESUMEN
Although defined more broadly, exposure science has mainly focused on exposures to environmental chemicals and related stressors, such as airborne particulate matter. There is an opportunity for exposure science to contribute more substantially to improving public health by devoting more attention to microorganisms as key stressors and agents in exposure. The discovery that pathogenic microbes cause disease in humans precipitated a revolution in public health science and disease prevention. With a continued global urgency to address spread of pathogenic microbes, contributions of microorganisms to both infectious and noninfectious processes merit more attention from the exposure science community. Today, discoveries of the importance of the human microbiome as a determinant of health and disease are precipitating a second revolution. Emerging knowledge creates a major opportunity to expand the scope of exposure science to incorporate the human microbiome as a target and modulator of exposure. A study committee of the National Academies of Sciences, Engineering, and Medicine has defined a research strategy to address health risks that pertain to the interaction of environmental chemicals with the human microbiome. Some aspects of this strategy pose important challenges and opportunities for the exposure science community.
Asunto(s)
Exposición a Riesgos Ambientales/estadística & datos numéricos , Salud Ambiental/tendencias , Medicina Ambiental/tendencias , Infectología/tendencias , Enfermedades Transmisibles/microbiología , Humanos , Salud PúblicaRESUMEN
BACKGROUND: The guidelines addressed the evidence-based indications for the management of children with acute infectious diarrhea in Chinese pediatric population. DATA SOURCES: The experts group of evidence development put forward clinical problems, collects evidence, forms preliminary recommendations, and then uses open-ended discussions to form recommendations. The literature review was done for developing this guideline in databases including PubMed, Cochrane, EMBASE, China Biomedical Database, and Chinese Journal Full-text Database up to June 2013. Search the topic "acute diarrhea" or "enteritis" and "adolescent" or "child" or "Pediatric patient" or "Baby" or "Infant". RESULTS: For the treatment of mild, moderate dehydration, hypotonic oral rehydration solutions (ORS) are strongly recommended. Intravenous (IV) rehydration is recommended for severe dehydration, with a mixture of alkali-containing dextrose sodium solution. Nasogastric feeding tube rehydration is used for children with severe dehydration without IV infusion conditions with ORS solution. Regular feeding should resume as soon as possible after oral rehydration or IV rehydration. The lactose-free diet can shorten the diarrhea duration. Zinc supplements are recommended in children with acute infectious diarrhea. Saccharomyces boulardii and Lactobacillus Rhamnus are recommended to be used in acute watery diarrhea. Saccharomyces boulardii is recommended in children with antibiotic-associated diarrhea as well. Montmorillonite and Racecadotril (acetorphan) can improve the symptoms of diarrhea or shorten the course of acute watery diarrhea. Antibiotics are recommended with dysenteric-like diarrhea, suspected cholera with severe dehydration, immunodeficiency, and premature delivery children with chronic underlying disease; otherwise, antibiotics are not recommended. CONCLUSION: The principles of the most controversial treatments with of acute infectious disease are reaching to a consensus in China.
Asunto(s)
Enfermedades Transmisibles/terapia , Diarrea/microbiología , Diarrea/terapia , Fluidoterapia/métodos , Guías de Práctica Clínica como Asunto , Enfermedad Aguda , Antibacterianos/uso terapéutico , Niño , Preescolar , China/epidemiología , Enfermedades Transmisibles/epidemiología , Enfermedades Transmisibles/microbiología , Deshidratación/prevención & control , Diarrea/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Infusiones Intravenosas , Masculino , Probióticos/uso terapéutico , Pronóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
OBJECTIVE: Infectious diseases are one of the prime causes of death worldwide. An innovative sequence specific editing technology "Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)" has been tested on a broad range of microorganisms to target and destroy invading foreign DNA to human cells or tissues. This study aimed to discuss the mechanism and therapeutic usage of CRISPR/Cas9 genome editing technology in the management of various infectious disease pathogens. MATERIALS AND METHODS: We conducted a broad search of the English-language literature in "PubMed" using the search terms "CRISPR", "Cas-9", "Genome editing", "Gene therapy", "infectious disease pathogens". All the articles were reviewed and required information was recorded. RESULTS: CRISPR technology is used to modify and modulate the gene expression in biomedical research and therapeutic development. This technology facilitates the understanding of fundamental biology and broadens the horizon of treatments of germ-laden conditions. CONCLUSIONS: The applications of CRISPR technology are widely established in the diagnosis and treatment of various bacterial, viral, fungal and parasitic infectious diseases. CRISPR technology is a simple, efficient and tested on a broad range of microorganisms to rectify disease-associated genetic defects and destroy invading foreign DNA to human cells or tissues.
Asunto(s)
Sistemas CRISPR-Cas , Enfermedades Transmisibles/genética , Enfermedades Transmisibles/terapia , Edición Génica/métodos , Terapia Genética/métodos , Enfermedades Transmisibles/microbiología , HumanosRESUMEN
One of the main issues with phage therapy from its earliest days has been the selection of appropriate disease targets. In early work, when the nature of bacteriophages was unknown, many inappropriate targets were selected, including some now known to have no bacterial involvement whatsoever. More recently, with greatly increased understanding of the highly specific nature of bacteriophages and of their mechanisms of action, it has been possible to select indications with an increased chance of a successful therapeutic outcome. The factors to be considered include the characteristics of the infection to be treated, the characteristics of the bacteria involved, and the characteristics of the bacteriophages themselves. At a later stage all of this information then informs trial design and regulatory considerations. Where the work is undertaken towards the development of a commercial product it is also necessary to consider the planned market, protection of intellectual property, and the sourcing of funding to support the work. It is clear that bacteriophages are not a "magic bullet". However, with careful and appropriate selection of a limited set of initial targets, it should be possible to obtain proof of concept for the many elements required for the success of phage therapy. In time, success with these initial targets could then support more widespread use.
Asunto(s)
Bacteriófagos , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/terapia , Terapia de Fagos , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacterias/efectos de los fármacos , Bacterias/virología , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/terapia , Bacteriófagos/fisiología , Ensayos Clínicos como Asunto , Vías de Administración de Medicamentos , Evaluación Preclínica de Medicamentos , Farmacorresistencia Bacteriana , HumanosRESUMEN
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: The risk and spectrum of infections in patients receiving CD22-targeted agents (i.e. inotuzumab ozogamicin) are similar to those observed with anti-CD20 antibodies. Anti-Pneumocystis prophylaxis and monitoring for cytomegalovirus (CMV) infection is recommended for patients receiving CD30-targeted agents (brentuximab vedotin). Due to the scarcity of data, the risk posed by CD33-targeted agents (gemtuzumab ozogamicin) cannot be assessed. Patients receiving CD38-targeted agents (i.e. daratumumab) face an increased risk of varicella-zoster virus (VZV) infection. Therapy with CD40-targeted agents (lucatumumab or dacetuzumab) is associated with opportunistic infections similar to those observed in hyper-IgM syndrome, and prevention strategies (including anti-Pneumocystis prophylaxis and pre-emptive therapy for CMV infection) are warranted. SLAMF-7 (CD319)-targeted agents (elotuzumab) induce lymphopenia and increase the risk of infection (particularly due to VZV). The impact of CCR4-targeted agents (mogamulizumab) on infection susceptibility is difficult to distinguish from the effect of underlying diseases and concomitant therapies. However, anti-Pneumocystis and anti-herpesvirus prophylaxis and screening for chronic hepatitis B virus (HBV) infection are recommended. IMPLICATIONS: Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.
Asunto(s)
Antígenos de Superficie/efectos de los fármacos , Terapia Biológica/efectos adversos , Enfermedades Transmisibles/terapia , Terapia Molecular Dirigida/efectos adversos , ADP-Ribosil Ciclasa 1/efectos de los fármacos , Antígenos de Superficie/inmunología , Terapia Biológica/métodos , Antígenos CD40/efectos de los fármacos , Ensayos Clínicos como Asunto , Enfermedades Transmisibles/inmunología , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/virología , Consenso , Humanos , Huésped Inmunocomprometido , Antígeno Ki-1/efectos de los fármacos , Linfocitos/efectos de los fármacos , Glicoproteínas de Membrana/efectos de los fármacos , Terapia Molecular Dirigida/métodos , Células Mieloides/efectos de los fármacos , Receptores CCR4/efectos de los fármacos , Lectina 2 Similar a Ig de Unión al Ácido Siálico/efectos de los fármacos , Lectina 3 Similar a Ig de Unión al Ácido Siálico/efectos de los fármacos , Familia de Moléculas Señalizadoras de la Activación Linfocitaria/efectos de los fármacosRESUMEN
Protein-protein interaction (PPI) inhibitors are a rapidly expanding class of therapeutics. Recent advances in our understanding of PPIs and success of early examples of PPI inhibitors demonstrate the feasibility of targeting PPIs. This review summarizes the techniques used for the discovery and optimization of a diverse set PPI inhibitors, focusing on the development of PPI inhibitors as new antibacterial and antiviral agents. We close with a summary of the advances responsible for making PPI inhibitors realistic targets for therapeutic intervention and brief outlook of the field.
Asunto(s)
Antibacterianos/farmacología , Antivirales/farmacología , Enfermedades Transmisibles/tratamiento farmacológico , Inhibidores de Fusión de VIH/farmacología , Inhibidores de Integrasa VIH/farmacología , Proteínas del Virus de la Inmunodeficiencia Humana/antagonistas & inhibidores , Antibacterianos/química , Antivirales/química , Bacterias/efectos de los fármacos , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/virología , Inhibidores de Fusión de VIH/química , Inhibidores de Integrasa VIH/química , Interacciones Microbiota-Huesped/efectos de los fármacos , Proteínas del Virus de la Inmunodeficiencia Humana/metabolismo , HumanosRESUMEN
The interaction between the human microbiome and immune system has an effect on several human metabolic functions and impacts our well-being. Additionally, the interaction between humans and microbes can also play a key role in determining the wellness or disease status of the human body. Dysbiosis is related to a plethora of diseases, including skin, inflammatory, metabolic, and neurological disorders. A better understanding of the host-microbe interaction is essential for determining the diagnosis and appropriate treatment of these ailments. The significance of the microbiome on host health has led to the emergence of new therapeutic approaches focused on the prescribed manipulation of the host microbiome, either by removing harmful taxa or reinstating missing beneficial taxa and the functional roles they perform. Culturing large numbers of microbial taxa in the laboratory is problematic at best, if not impossible. Consequently, this makes it very difficult to comprehensively catalog the individual members comprising a specific microbiome, as well as understanding how microbial communities function and influence host-pathogen interactions. Recent advances in sequencing technologies and computational tools have allowed an increasing number of metagenomic studies to be performed. These studies have provided key insights into the human microbiome and a host of other microbial communities in other environments. In the present review, the role of the microbiome as a therapeutic agent and its significance in human health and disease is discussed. Advances in high-throughput sequencing technologies for surveying host-microbe interactions are also discussed. Additionally, the correlation between the composition of the microbiome and infectious diseases as described in previously reported studies is covered as well. Lastly, recent advances in state-of-the-art bioinformatics software, workflows, and applications for analysing metagenomic data are summarized.
Asunto(s)
Enfermedades Transmisibles/microbiología , Secuenciación de Nucleótidos de Alto Rendimiento/tendencias , Interacciones Microbiota-Huesped/genética , Interacciones Huésped-Patógeno/genética , Metagenómica/tendencias , Microbiota/fisiología , Enfermedades Transmisibles/etiología , Biología Computacional/tendencias , Disbiosis/complicaciones , Predicción , Secuenciación de Nucleótidos de Alto Rendimiento/instrumentación , Humanos , Nanotecnología/métodosRESUMEN
Eugenol is a hydroxyphenyl propene, naturally occurring in the essential oils of several plants belonging to the Lamiaceae, Lauraceae, Myrtaceae, and Myristicaceae families. It is one of the major constituents of clove (Syzygium aromaticum (L.) Merr. & L.M. Perry, Myrtaceae) oil and is largely used in both foods and cosmetics as a flavoring agent. A large body of recent scientific evidence supports claims from traditional medicine that eugenol exerts beneficial effects on human health. These effects are mainly associated with antioxidant and anti-inflammatory activities. Eugenol has also shown excellent antimicrobial activity in studies, being active against fungi and a wide range of gram-negative and gram-positive bacteria. The aim of this review is to analyze scientific data from the main published studies describing the antibacterial and antifungal activities of eugenol targeting different kind of microorganisms, such as those responsible for human infectious diseases, diseases of the oral cavity, and food-borne pathogens. This article also reports the effects of eugenol on multi-drug resistant microorganisms. On the basis of this collected data, eugenol represents a very interesting bioactive compound with broad spectrum antimicrobial activity against both planktonic and sessile cells belonging to food-decaying microorganisms and human pathogens.
Asunto(s)
Antibacterianos/farmacología , Antifúngicos/farmacología , Bacterias/efectos de los fármacos , Enfermedades Transmisibles/tratamiento farmacológico , Eugenol/farmacología , Hongos/efectos de los fármacos , Aceites Volátiles/farmacología , Antiinflamatorios/farmacología , Antioxidantes/farmacología , Membrana Celular/efectos de los fármacos , Enfermedades Transmisibles/microbiología , Enfermedades Transmitidas por los Alimentos/tratamiento farmacológico , Enfermedades Transmitidas por los Alimentos/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Syzygium/químicaRESUMEN
Medical science is pitted against an ever-increasing rise in antibiotic tolerant microorganisms. Concurrently, during the past decade, biofilms have garnered much attention within research and clinical practice. Although the significance of clinical biofilms is becoming very apparent, current methods for diagnostics and direction of therapy plans in many hospitals do not reflect this knowledge; with many of the present tools proving to be inadequate for accurately mimicking the biofilm phenomenon. Based on current findings, we address some of the fundamental issues overlooked by clinical labs: the paradigm shifts that need to occur in assessing chronic wounds; better simulation of physiological conditions in vitro; and the importance of incorporating polymicrobial populations into biofilm models. In addition, this review considers using a biofilm relevant in vitro model for cultivating and determining the antibiotic tolerance and susceptibility of microorganisms associated with chronic wounds. This model presents itself as a highly rapid and functional tool that can be utilized by hospitals in an aim to improve bedside treatments.
Asunto(s)
Antibacterianos/uso terapéutico , Biopelículas/crecimiento & desarrollo , Bacterias Gramnegativas/crecimiento & desarrollo , Bacterias Grampositivas/crecimiento & desarrollo , Infección de Heridas/microbiología , Heridas y Lesiones/microbiología , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/microbiología , Farmacorresistencia Bacteriana , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Gramnegativas/patogenicidad , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/patogenicidad , Humanos , Pruebas de Sensibilidad Microbiana , Infección de Heridas/tratamiento farmacológico , Infección de Heridas/patologíaRESUMEN
Antimicrobial herbal compounds are one of the important medical resources, and in order to help alleviate the spread of the pediatric infectious diseases, identification of additional bioactive phytochemicals and herbal extracts will be practical in treating illnesses. In the present work, antimicrobial activities various extracts of Tordylium persicum Boiss. & Hausskn aerial parts were determined against five Gram-positive bacteria, five Gram-negative bacteria, two fungi, and Echinococcus granulosus. Antimicrobial activities were assayed using both disk diffusion and microbroth dilution methods. Scolicidal activity was assayed by the Smyth and Barrett method. Also total phenol and total flavonoid contents for plant extracts were assayed. Results showed that the methanolic extract was more effective on all microbes. The results showed that Streptococcus pyogenes was the most susceptible to the methanolic extract (MIC = 25.9 ± 0.0 µg/mL), while Proteus vulgaris was the most resistant strain (MIC = 295.3 ± 0.0 µg/mL) among all bacteria evaluated. The extracts showed significant activity versus E. granulosus (P < 0.5) with dose-dependent inhibitions of the protoscolices. The high concentration of total polyphenolics (294.5 ± 0.1 GAE/g DW) and flavonoids (105.7 ± 0.3 mg CE/g DW) may be responsible for these activities. Our study is first evaluation on antimicrobial and scolicidal activities of T. persicum. Due to the appearance of antibiotic-resistance, ourstudy suggested that methanol extracts of this plant are appropriate candidate for traditional curative uses and it can be utilized in the pediatric infectious disease therapy, especially pediatric infectious disease.
Asunto(s)
Antiinfecciosos/farmacología , Apiaceae/química , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Extractos Vegetales/farmacología , Antiinfecciosos/química , Antiinfecciosos/uso terapéutico , Apiaceae/metabolismo , Preescolar , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/microbiología , Farmacorresistencia Bacteriana/efectos de los fármacos , Flavonoides/química , Flavonoides/aislamiento & purificación , Flavonoides/farmacología , Hongos/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Componentes Aéreos de las Plantas/química , Componentes Aéreos de las Plantas/metabolismo , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , Polifenoles/química , Polifenoles/aislamiento & purificación , Polifenoles/farmacologíaRESUMEN
BACKGROUND: The prevalence of central venous catheter (CVC)-related blood-stream infections (CRBSI), infecting agents and the effectiveness of antibiotic therapy were evaluated in 172 adult patients on Home Parenteral Nutrition (HPN) at the Clinical Nutrition Outpatient Unit of Federico II University Hospital in Naples, Italy. MATERIALS AND METHODS: The study population consisted of 127 oncological (74%) and 45 (26%) non-oncological patients, for a total of 53,818 (median 104; range 14-1080) CVC days. RESULTS: Ninety-four CRBSIs were diagnosed on 238 CVC (infection rate 1.74/1000 CVC days). Coagulase negative (CoNs) Staphylococci were the most frequently infecting agents (52.8% as single agent) with 17.1% Staphylococcus epidermidis infections. Eighty-three percent S. epidermidis were beta-lattamase producer (BLACT), 66.6% methicillin-resistant (MR) and 55.5% had a MIC for Vancomicin ≥1. Gram-negative bacteria represented 18.6% infections, fungi 7.1%, finally 15% infections were polymicrobial. Previous catheterizations and the presence of an enterocutaneous stoma were significantly related with a higher infection risk (p < 0.0001 in both cases). CONCLUSIONS: CRBSI and antibiotic resistance of infecting agents remain an important challenge in adult patients on HPN; an active research on strategies to counteract the phenomena is required.
Asunto(s)
Bacteriemia/epidemiología , Infecciones Relacionadas con Catéteres/epidemiología , Catéteres Venosos Centrales/microbiología , Enfermedades Transmisibles/epidemiología , Nutrición Parenteral en el Domicilio/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos , Bacteriemia/etiología , Infecciones Relacionadas con Catéteres/sangre , Infecciones Relacionadas con Catéteres/etiología , Infecciones Relacionadas con Catéteres/microbiología , Catéteres Venosos Centrales/efectos adversos , Enfermedades Transmisibles/sangre , Enfermedades Transmisibles/microbiología , Femenino , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
Ginseng is commonly used in traditional Chinese medicine as a tonic and an adaptogen to reduce fatigue and boost the immune system. In recent years, ginseng extracts are shown to have both bacteriostatic and bactericidal actions and seem to exert their effects by several mechanisms, including disruption of biofilms, inhibition of quorum-sensing and virulence factors, and altering motility. Also, ginseng extracts are shown to have antifungal properties as demonstrated by their ability to inhibit the growth of several mold and yeast species. Extracts from ginseng root have a strong antiviral activity against the RNA viruses in cell cultures and animal models. In addition to the antimicrobial activities, ginseng extracts are shown to possess immunomodulatory properties involved in the amelioration of infections. The present paper describes the antimicrobial effects of ginseng and its extracts.